A STUDY TO ASSESS EFFICACY, SAFTETY AND PHARMACOKINETICS OF EYU688 IN HEALTHY PARTICIPANTS CHALLENGED WITH DENGUE SEROTYPE 2

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 75N93019D00031-0-759302300004-1

Grant search

Key facts

  • Disease

    N/A

  • Start & end year

    2023
    2025
  • Known Financial Commitments (USD)

    $3,096,871
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    ASSOCIATE PROFESSOR Anna Durbin
  • Research Location

    United States of America
  • Lead Research Institution

    JOHNS HOPKINS UNIVERSITY
  • Research Priority Alignment

    N/A
  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Phase 2 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase II

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

To support a phase two clinical trial to evaluate a dengue vaccine candidate.